NeoStem Chairman and CEO to be Honored at the Moves 2010 Power Women Awards

NEW YORK, Nov. 9, 2010 /PRNewswire/ -- NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, today announced that NeoStem's Chairman and CEO, Dr. Robin L. Smith, M.D., MBA, will be honored tonight at Moves Magazine's 2010 Power Women Awards Dinner & Ceremony beginning at 6:30 pm at the Astor Center, 399 Lafayette Street, New York City.

This event marks the seventh year of the Moves Power Women Awards. The event will be hosted by Kerry Washington, an actor and member of the President's Committee on the Arts and Humanities. According to Moves Magazine, the 2010 Power Women Awards honors "successful and influential women of substance… power women."

Robin Smith commented, "I am honored to be among such fabulous women. As an entrepreneur, philanthropist, and physician, my life is centered around others and my greatest reach will be through my work at NeoStem, where we focus on adult stem cells and search for ways to repair damaged tissues and find treatments and cures for many debilitating diseases and conditions. We also enable healthy adults to have their stem cells stored should they be needed in the future as a Bio-insurance."

About NeoStem, Inc.

NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that are focused on enabling people to donate and store their own (autologous) stem cells for their personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL™ Technology which uses very small embryonic-like stem cells, shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include the future of VSEL™ Technology and adult stem cells as a viable treatment option, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.


For more information, please contact


NeoStem, Inc.


Robin Smith


Phone: +1 (212) 584-4174


E-mail: [email protected]neostem.com


http://www.neostem.com






SOURCE NeoStem, Inc.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.